The DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index.
An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors
Open accessAbstract
An implantable microdevice is demonstrated to release microdoses of multiple drugs into confined regions of tumors and allows for assessment of each drug’s efficacy to identify optimal therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There have been recent advancements in this arena involving implantable devices, but these approaches are currently only compatible with solid tumors, and require tumors of a minimum size that are easily accessible30.”
From Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate (2016) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Intra-tumour heterogeneity: a looking glass for cancer?
Marusyk, A., Almendro, V., & Polyák, K. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3261 · Cited by 2,058
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
Small-scale systems for in vivo drug delivery
LaVan, D. A., McGuire, T., & Langer, R. (2003) · Nature Biotechnology · doi:10.1038/nbt876 · Cited by 1,314
Self-citationSequence analysis of mutations and translocations across breast cancer subtypes
Banerji, S. O., Cibulskis, K., Rangel‐Escareño, C., Brown, K., Carter, S. L., Frederick, A. M., Lawrence, M. S., Sivachenko, A., Sougnez, C. L., Zou, L., et al. (2012) · Nature · doi:10.1038/nature11154 · Cited by 1,181
Self-citationWidespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134
Combinatorial drug therapy for cancer in the post-genomic era
Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070
The productivity crisis in pharmaceutical R&D
Pammolli, F., Magazzini, L., & Riccaboni, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3405 · Cited by 918
Overview of resistance to systemic therapy in patients with breast cancer
Gonzalez-Angulo, A. M., Morales-Vasquez, F., & Hortobagyi, G. N. (2007) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-74039-3_1 · Cited by 904
Triple-Negative Breast Cancer: An Unmet Medical Need
Hudis, C. A., & Gianni, L. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s1-01 · Cited by 794
Triple-negative breast cancer: disease entity or title of convenience?
Carey, L., Winer, E. P., Viale, G., Cameron, D., & Gianni, L. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.154 · Cited by 791
Sirotnak, F. M., Zakowski, M. F., Miller, V. A., Scher, H. I., & Kris, M. G. (2000) · PubMed · Cited by 761
Engstrom, P. F., Arnoletti, J. P., Benson, A. B., Chen, Y., Choti, M. A., Cooper, H. S., Covey, A. M., Dilawari, R. A., Early, D. S., Enzinger, P. C., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0056 · Cited by 683
Lee, M. J., Ye, A. S., Gardino, A. K., Heijink, A. M., Sorger, P. K., MacBeath, G., & Yaffe, M. B. (2012) · Cell · doi:10.1016/j.cell.2012.03.031 · Cited by 681
Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study
Roychowdhury, S., Iyer, M. K., Robinson, D. R., Lonigro, R. J., Wu, Y.-M., Cao, X., Sundaram, S. K., Sam, L. T., Balbin, O. A., Quist, M. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003161 · Cited by 638
Discovery of small molecule cancer drugs: Successes, challenges and opportunities
Hoelder, S., Clarke, P. A., & Workman, P. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.004 · Cited by 591
A BioMEMS Review: MEMS Technology for Physiologically Integrated Devices
Grayson, A. C. R., Shawgo, R. S., Johnson, A. M., Flynn, N. T., Li, Y., Cima, M. J., & Langer, R. (2004) · Proceedings of the IEEE · doi:10.1109/jproc.2003.820534 · Cited by 562
Self-citationBody condition scoring: a rapid and accurate method for assessing health status in mice.
Ullman-Culleré, M., & Foltz, C. J. (1999) · PubMed · Cited by 531
Nakasone, E. S., Askautrud, H. A., Kees, T., Park, J.-H., Plaks, V., Ewald, A. J., Fein, M. R., Rasch, M. G., Tan, Y.-X., Qiu, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.017 · Cited by 485
First-in-Human Testing of a Wirelessly Controlled Drug Delivery Microchip
Farra, R., Sheppard, N. F., McCabe, L., Neer, R. M., Anderson, J., Santini, J. T., Cima, M. J., & Langer, R. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003276 · Cited by 449
Self-citationDai, C.-L., Tiwari, A. K., Wu, C.-P., Su, X.-D., Wang, S.-R., Liu, D.-G., Ashby, C. R., Huang, Y., Robey, R. W., Liang, Y.-J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0499 · Cited by 386
Personalized medicine in oncology: the future is now
Schilsky, R. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3181 · Cited by 347
Holbeck, S. L., Collins, J. M., & Doroshow, J. H. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0106 · Cited by 316
Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed?
Overman, M. J., Modak, J. M., Kopetz, S., Murthy, R., Yao, J. C., Hicks, M. E., Abbruzzese, J. L., & Tam, A. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1718 · Cited by 315
Fung, L. K., Ewend, M. G., Sills, A. K., Sipos, E. P., Thompson, R. C., Watts, M., Colvin, O. M., Brem, H., & Saltzman, W. M. (1998) · PubMed · Cited by 289
Spending on new drug development1
Adams, C., & Brantner, V. V. (2009) · Health Economics · doi:10.1002/hec.1454 · Cited by 277
Almendro, V., Cheng, Y.-K., Randles, A. P., Itzkovitz, S., Marusyk, A., Ametller, E., González, X., Muñoz-Mateu, M., Russnes, H. G., Helland, Å., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2013.12.041 · Cited by 274
Adaptive clinical trials in oncology
Berry, D. A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.165 · Cited by 268
Compressing drug development timelines in oncology using phase '0' trials
Kummar, S., Kinders, R. J., Rubinstein, L., Parchment, R. E., Murgo, A. J., Collins, J. M., Pickeral, O. K., Low, J. A., Steinberg, S. M., Gutierrez, M. E., et al. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2066 · Cited by 214
High-Throughput Methods for Combinatorial Drug Discovery
Sun, X., Vilar, S., & Tatonetti, N. P. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006667 · Cited by 204
Genetic and Phenotypic Diversity in Breast Tumor Metastases
Almendro, V., Kim, H. J., Cheng, Y.-K., Gönen, M., Itzkovitz, S., Argani, P., van Oudenaarden, A., Sukumar, S. V., Michor, F., & Polyák, K. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2357-t · Cited by 176
Tao, J. J., Castel, P., Radosevic‐Robin, N., Elkabets, M., Auricchio, N., Aceto, N., Weitsman, G. E., Barber, P. R., Vojnovic, B., Ellis, H., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2005125 · Cited by 167
Self-citationManagement of breast cancer with targeted agents: importance of heterogenicity
Cosimo, S. D., & Baselga, J. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.234 · Cited by 159
Self-citationThe future of drug development: advancing clinical trial design
Orloff, J. J., Douglas, F. L., Pinheiro, J. C., Levinson, S. L., Branson, M., Chaturvedi, P. R., Ette, E., Gallo, P. P., Hirsch, G., Mehta, C. R., et al. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd3025 · Cited by 159
Overcoming implementation challenges of personalized cancer therapy
Meric‐Bernstam, F., & Mills, G. B. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.127 · Cited by 150
Ross, J. S., Wang, K., Al-Rohil, R. N., Nazeer, T., Sheehan, C. E., Otto, G. A., He, J., Palmer, G. A., Yelensky, R., Lipson, D., et al. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.135 · Cited by 149
Drug development and clinical trials—the path to an approved cancer drug
Rubin, E. H., & Gilliland, D. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.22 · Cited by 135
Baker, J. H. E., Lindquist, K. E., Huxham, L. A., Kyle, A. H., Sy, J., & Minchinton, A. I. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4465 · Cited by 125
Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments
Merz, F., Gaunitz, F., Dehghani, F., Renner, C., Meixensberger, J., Gutenberg, A., Giese, A., Schopow, K., Hellwig, C. T., Schäfer, M., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not003 · Cited by 123
Evaluation of different fiducial markers for image-guided radiotherapy and particle therapy
Habermehl, D., Henkner, K., Ecker, S., Jäkel, O., Debus, J., & Combs, S. E. (2013) · Journal of Radiation Research · doi:10.1093/jrr/rrt071 · Cited by 94
Guidelines for Assessing the Health and Condition of Mice
Foltz, C. J., & Ullman-Culleré, M. (1999) · Laboratory animal science · Cited by 87
Correction: Reversal of Multidrug Resistance by Lapatinib
(2008) · Cancer Research · doi:10.1158/0008-5472.can-68-24-cor · Cited by 86
Garner, R. C., & Lappin, G. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02575.x · Cited by 79
Microregional Effects of Gemcitabine in HCT-116 Xenografts
Huxham, L. A., Kyle, A. H., Baker, J. H. E., Nykilchuk, L. K., & Minchinton, A. I. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0986 · Cited by 79
Spending on New Drug DevelopmentPreprint
Adams, C., & Brantner, V. V. (2005) · SSRN Electronic Journal · doi:10.2139/ssrn.869765 · Cited by 66
Time-and concentration-dependent penetration of doxorubicin in prostate tumors
Zheng, J., Chen, C., Au, J. L. ‐., & Wientjes, M. G. (2001) · AAPS PharmSci · doi:10.1208/ps030215 · Cited by 63
Sterzing, F., Engenhart‐Cabillic, R., Flentje, M. P., & Debus, J. (2011) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2011.0274 · Cited by 61
Impact of Genomics on Personalized Cancer Medicine
Arteaga, C. L., & Baselga, J. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2019 · Cited by 57
Self-citationMulti‐Reservoir Bioadhesive Microdevices for Independent Rate‐Controlled Delivery of Multiple Drugs
Chirra, H. D., & Desai, T. A. (2012) · Small · doi:10.1002/smll.201201367 · Cited by 54
Chang, L.-C., Liang, J. F., Lee, H.-F., Lee, L. M., & Yang, V. C.-M. (2001) · AAPS PharmSci · doi:10.1208/ps030318 · Cited by 52
Mahajan, R., & Gupta, K. (2010) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/0975-7406.72130 · Cited by 49
Denisov, E. V., Литвяков, Н. В., Zavyalova, M. V., Михайлович, П. В., Vtorushin, S. V., Tsyganov, M. M., Gerashchenko, T. S., Garbukov, Е. Y., Slonimskaya, E. M., & Чердынцева, Н. В. (2014) · Scientific Reports · doi:10.1038/srep04709 · Cited by 43
Redefining Clinical Trials: The Age of Personalized Medicine
Vaidyanathan, G. (2012) · Cell · doi:10.1016/j.cell.2012.02.041 · Cited by 38
Fang, C., Avis, I. M., Salomon, D. S., & Cuttitta, F. F. (2013) · Journal of Cancer · doi:10.7150/jca.6780 · Cited by 18
In Vitro Antibiotic Testing and Its Relationship to Clinical Activity
Mouton, Y., & Dubreuil, L. (1997) · Journal of Chemotherapy · doi:10.1080/1120009x.1997.12113194 · Cited by 3
Research works printed but not linked: 1
- U.S. Food and Drug Administration Investigational Device Exemptions (IDEs) for Early Feasibility Medical Device Clinical Studies Including Certain First in Human (FIH) Studies—Guidance for Industry and Food (U.S. Food and Drug Administration Silver Spring MD 2011) pp. 1–40.
Cited by
Sorted by citations
A view on drug resistance in cancer
Vasan, N., Baselga, J., & Hyman, D. M. (2019) · Nature · doi:10.1038/s41586-019-1730-1 · Cited by 2,770
Self-citationGeller, L. T., Barzily-Rokni, M., Danino, T., Jonas, O. H., Shental, N., Nejman, D., Gavert, N., Zwang, Y., Cooper, Z. A., Shee, K., et al. (2017) · Science · doi:10.1126/science.aah5043 · Cited by 1,817
Self-citationEmerging Frontiers in Drug Delivery
Tibbitt, M. W., Dahlman, J. E., & Langer, R. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b09974 · Cited by 1,009
Self-citationPersonalized medicine: motivation, challenges, and progress
Goetz, L. H., & Schork, N. J. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.05.006 · Cited by 976
A new chapter in pharmaceutical manufacturing: 3D-printed drug products
Norman, J. J., Madurawe, R. D., Moore, C. M. V., Khan, M. A., & Khairuzzaman, A. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.03.001 · Cited by 832
Metadata
- Authors
- Jonas, O., Landry, H. M., Fuller, J. E., Santini, J. T., Baselga, J., Tepper, R. I., Cima, M. J., & Langer, R.
- Affiliations
- Koch Institute for Integrative Cancer Research At MIT (US)
- Kibur Medical Inc., 29 Newbury Street, Suite 301, Boston, MA 02116, USA.
- Memorial Sloan Kettering Cancer Center (US)
- The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
- Venue
- Science Translational Medicine
- Published
- 2015-04-22
- Volume
- 7
- Issue
- 284
- Pages
- 284ra57-284ra57
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC4825177
- OpenAlex
- W2161687028
- Cited by
- 189
- References
- 58
- Citations by year
- 2026: 7 · 2025: 15 · 2024: 9 · 2023: 10 · 2022: 30 · 2021: 17 · 2020: 20 · 2019: 14 · 2018: 12 · 2017: 19 · 2016: 22 · 2015: 14
- FWCI
- 11.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- Funders
- National Cancer Institute (R21-CA177391)
- Kibur Medical Inc.
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Keywords
- implantable microdevices, anticancer drug response, tumor microenvironment, combination therapy, local drug delivery, predictive biomarkers, minimally invasive biopsy, tumor models, precision oncology, drug development
- MeSH terms
- Animals, Antineoplastic Agents, Biopsy, Calibration, Dose-Response Relationship, Drug, Doxorubicin, Drug Screening Assays, Antitumor, Humans, Neoplasms, Polyethylene Glycols, Polymers, Prognosis, Biomarkers, Tumor, Drug Delivery Systems, Drug Monitoring, Apoptosis, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
